These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28942006)

  • 1. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
    Kim MS; Baek IH
    Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of myricetin on the bioavailability of carvedilol in rats.
    Lee W; Woo ER; Choi JS
    Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
    Lim TH; Cho YA; Choi DH
    J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
    Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
    Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
    Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study.
    Huang Y; Zheng S; Pan Y; Li T; Xu ZS; Shao MM
    J Pharm Biomed Anal; 2016 Sep; 128():184-190. PubMed ID: 27262994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
    Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats.
    Abrudan MB; Muntean DM; Gheldiu AM; Neag MA; Vlase L
    Pharmacology; 2017; 99(3-4):139-143. PubMed ID: 28052289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
    Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
    Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G
    Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
    Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
    Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
    Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
    Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
    Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats.
    Hokama N; Hobara N; Sakai M; Kameya H; Ohshiro S; Sakanashi M
    J Pharm Pharmacol; 2002 Jun; 54(6):821-5. PubMed ID: 12078998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rerouting cardiovascular management following gastric bypass surgery: Dose optimization of carvedilol using population-based analysis.
    Yamamoto PA; Vozmediano V; Cristofoletti R; Jiang J; Schmittgen TD; de Gaitani CM; Kemp R; Sankarankutty AK; Dos Santos JS; Salgado Junior W; de Moraes NV
    Br J Clin Pharmacol; 2024 Sep; 90(9):2223-2235. PubMed ID: 38852609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
    Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
    Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.